Related Experiment Video

Updated: Aug 21, 2026

Accessing the Cytotoxicity and Cell Response to Biomaterials
09:46

Accessing the Cytotoxicity and Cell Response to Biomaterials

Published on: July 8, 2021

Correspondence on 'Cardiovascular toxicities associated with bispecific T-cell engager therapy' by Sayed et al

Yoshihiro Noguchi1, Miao Yan2,3,4, Tomoya Tachi5

  • 1Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu, Gifu, Japan noguchiy@gifu-pu.ac.jp.

Journal for Immunotherapy of Cancer
|April 22, 2024
PubMed
Abstract

No abstract available in PubMed .

Keywords:
CardiotoxicityT cellTreatment related adverse event - trAE

More Related Videos

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Related Experiment Videos

Last Updated: Aug 21, 2026

Accessing the Cytotoxicity and Cell Response to Biomaterials
09:46

Accessing the Cytotoxicity and Cell Response to Biomaterials

Published on: July 8, 2021

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...

Articles linked to this work by shared authors, journal, and citation graph.

Large Language Models for World Health Organization-Uppsala Monitoring Centre Drug-Adverse Event Causality Assessment Using Food and Drug Administration Adverse Event Reporting System Cases: Comparative Performance Study.

Journal of medical Internet research·2026

Theoretical Framework and Key Considerations for Time-to-Onset Analysis in Spontaneous Reporting Systems.

Drug safety·2026

Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database.

The Journal of antimicrobial chemotherapy·2026

Sequence Symmetry Analysis of the Interrelationships Between Ramelteon and Parkinson's Disease.

Journal of pineal research·2025

Association Between Melatonin Receptor Agonists and Cardiac Arrhythmia; Disproportionality Analysis Studies Using Pharmacovigilance Databases.

Cardiovascular toxicology·2025

Comparison of dose rounding and drug vial optimization for reducing anticancer drug waste.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2025

Deep learning-based CT model for non-invasive prediction of tertiary lymphoid structures in pancreatic cancer: a multicenter study with prospective validation in an immunochemotherapy cohort.

Journal for immunotherapy of cancer·2026

Tumor cell-expressed OX40L enhances the efficacy of PD-1 axis blockade in non-small cell lung cancer.

Journal for immunotherapy of cancer·2026

Neoadjuvant chemoimmunotherapy with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-2): an open-label, single-arm, phase 2 study.

Journal for immunotherapy of cancer·2026

PLP1-triggered NOT gate to address neurotoxicity risk of PSMA-targeted prostate cancer therapy.

Journal for immunotherapy of cancer·2026

Epigenetic plus cytokine therapy induces stem-like CD8+ T-cell reservoirs and intratumoral immune niches to overcome anti-PD-1 resistance.

Journal for immunotherapy of cancer·2026

PRKX-mediated stabilization of PD-L1 characterizes an immunosuppressive gastric cancer subtype.

Journal for immunotherapy of cancer·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us